6 days Ago By ABMN Staff
Geode Capital Management LLC lessened its holdings in Agios Pharmaceuticals, Inc. ( NASDAQ:AGIO – Free Report ) by 0.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission.
The firm owned 1,349,651 shares of the biopharmaceutical company’s stock after selling 7,880 shares during the quarter. Geode Capital Management LLC owned 2.37% of Agios Pharmaceuticals worth $44,360,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors have also added to or reduced their stakes in AGIO. Franklin Resources Inc. grew its position in Agios Pharmaceuticals by 83.
0% during the 4th quarter. Franklin Resources Inc. now owns 66,461 shares of the biopharmaceutical company’s stock worth $2,184,000 after acquiring an additional 30,144 shares during the last quarter.
Alliancebernstein L.P. boosted its position in Agios Pharmaceuticals by 1.
2% during the 4th quarter. Alliancebernstein L.P.
now owns 61,500 shares of the biopharmaceutical company’s stock valued at $2,021,000 after buying an additional 708 shares during the period. Norges Bank bought a new stake in Agios Pharmaceuticals in the 4th quarter worth $4,768,000. NEOS Investment Management LLC raised its stake in shares of Agios Pharmaceuticals by 10.
9% during the fourth quarter. NEOS Investment Management LLC now owns 25,735 shares of the biopharmaceutical company’s stock valued at $846,000 after acquiring an additional 2,527 shares during the last quarter. Finally, Artisan Partners Limited Partnership boosted its holdings in shares of Agios Pharmaceuticals by 27.
4% during the fourth quarter. Artisan Partners Limited Partnership now owns 499,134 shares of the biopharmaceutical company’s stock worth $16,402,000 after purchasing an additional 107,292 shares during the period. Wall Street Analysts Forecast Growth Several equities research analysts have weighed in on the company.
Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. StockNews.com cut shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, February 14th.
Finally, HC Wainwright started coverage on shares of Agios Pharmaceuticals in a report on Monday, February 24th. They issued a “buy” rating and a $58.00 price objective for the company.
One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $56.
57. Agios Pharmaceuticals Stock Up 3.1 % Shares of AGIO opened at $27.
52 on Tuesday. The business’s 50 day moving average price is $31.25 and its 200-day moving average price is $39.
06. The stock has a market cap of $1.58 billion, a P/E ratio of 2.
43 and a beta of 0.83. Agios Pharmaceuticals, Inc.
has a 52 week low of $23.42 and a 52 week high of $62.58.
Agios Pharmaceuticals ( NASDAQ:AGIO – Get Free Report ) last announced its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.
69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.
51% and a net margin of 1,845.92%. On average, equities analysts anticipate that Agios Pharmaceuticals, Inc.
will post -6.85 EPS for the current year. Insider Activity at Agios Pharmaceuticals In other news, Director Jacqualyn A.
Fouse sold 7,497 shares of the firm’s stock in a transaction dated Thursday, April 10th. The shares were sold at an average price of $25.90, for a total transaction of $194,172.
30. Following the sale, the director now owns 149,220 shares of the company’s stock, valued at $3,864,798. This trade represents a 4.
78 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link . 4.
93% of the stock is owned by insiders. Agios Pharmaceuticals Profile ( Free Report ) Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.
Featured Articles Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals, Inc. ( NASDAQ:AGIO – Free Report ).
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter ..
